Theratechnologies FDA review yields favorable results Print E-mail
By Terika Ray   
Tuesday, 01 June 2010 03:03

“GMP securities called the stock undervalued…” Dow Jones, Oct. 6 2009. 
Theratechnologies Inc. is a biopharmaceutical company that discovers novel therapeutic products for development and commercialization.

"Undervalued" Theratechnologies Inc. (OTC:THTCF) (TSX:TH)

Theratechnologies (TSX:TH) announced May 27, that the U.S. Food and Drug Administration ("FDA" or the "Agency") Endocrinologic and Metabolic Drugs Advisory Committee recommended by a 16 to 0 unanimous vote that tesamorelin, a growth hormone releasing factor, should be granted marketing approval by the FDA for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy, based on a favorable benefit-risk profile.

The PDUFA date is July 27, 2010.  For more in depth information about Theratechnologies read the related article cited here.


"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus